Fig. 1

Effects of the use metformin during first-line chemo-immunotherapy in diffuse large B-cell lymphoma patients. Retrospective analysis of 264 patients at RPCCC diagnosed with DLBCL. Kaplan-Meier curves showing an improved progression-free survival (PFS) (a) and overall survival (OS) (b) based on metformin use in diabetic DLBCL patients. When the impact of metformin use during rituximab and systemic chemotherapy (doxorubicin-based poly-chemotherapy) was compared among all patients, diabetic patients on metformin (red line) vs. other glucose lowering agents (green line) had a statistically significant improvement in both PFS (90 months vs. 60 months, P = 0.036) and OS (100 months vs. 71 months, P = 0.039). There was a trend towards improved PFS (90 months vs. 83 months, P = 0.23) and OS (100 months vs 97 months, P = 0.25) even when compared to non-diabetic patients (blue line), but this difference did not reach statistical significance